Sorafenib , ≥99% , 284461-73-0

CAS NO.：284461-73-0

Empirical Formula: C21H16ClF3N4O3

Molecular Weight: 464.82

MDL number: MFCD06411450

EINECS: 608-209-4

PRODUCT Properties

• Melting point: 202-204°C
• Boiling point: 523.3±50.0 °C(Predicted)
• Density: 1.454±0.06 g/cm3(Predicted)
• vapor pressure: 0Pa at 25℃
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Chloroform (Slightly), DMSO (Slightly)
• pka: 12.89±0.70(Predicted)
• form: White to off-white solid.
• color: White to Off-White
• Water Solubility: 100μg/L at 20℃
• LogP: 3.3 at 25℃

Description and Uses

Sorafenib is a small molecular inhibitor of several kinases involved in tumor angiogenesis and proliferation, including, but not limited to, Raf (IC₅₀=12nM for Raf-1), VEGFR (IC₅₀=90nM for VEGFR-2 and IC₅₀=12nM for VEGFR-3), and platelet derived growth factor receptor (IC₅₀=57nM for PDGFR-b). Specifically, sorafenib blocks tumor progression by inhibiting cellular proliferation that is dependent on activation of the MAPK pathway (Raf) and/or inhibiting tumor angiogenesis through VEGFR and/or PDGFR. While it may be effective in the treatment of a variety of tumors, the first approvable indication is for renal cell carcinoma. Overall, the drug appears to be well tolerated by the majority of patients at the 400 mg b.i.d. continuous dosing. As an inhibitor of multiple kinases vital for tumor progression, sorafenib may possess wide-spectrum antitumor properties and may emerge as an effective weapon against a variety of solid tumors.

Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P280-P305+P351+P338
• Risk Statements: 68/20/21/22-37/38
• Safety Statements: 36-37-39
• HS Code: 29350090